Is there a role for proteomics in Peyronie's disease?

Journal of Sexual Medicine

Volumn 4, Issue 4 I, 2007, Pages 867-877

  Domes, Trustin ^a,b   De Young, Ling ^b,c   O'gorman, David B ^a,b,c   Gan, Bing Siang ^a,b,c   Bella, Anthony J ^d   Brock, Gerald ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Diagnostics; Peyronie's disease; Proteomics; Therapeutics

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CADHERIN; CALCINEURIN; CALCINEURIN A; CATENIN; COLLAGENASE; COLLAGENASE 4; DECORIN; DESMIN; DNA FRAGMENT; EARLY GROWTH RESPONSE FACTOR 1; ELASTIN; GAMMA SMOOTH MUSCLE ACTIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 28; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; NITRIC OXIDE; OSTEONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLEIOTROPHIN; PROTEOME; REACTIVE OXYGEN METABOLITE; RIBOSOME PROTEIN; SMAD7 PROTEIN; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UNCLASSIFIED DRUG;

BLADDER CANCER; DIAGNOSTIC VALUE; DNA MICROARRAY; EARLY CANCER; FIBROGENESIS; GENE EXPRESSION PROFILING; HUMAN; IMMUNOCYTOCHEMISTRY; MEDICAL LITERATURE; MOLECULAR DYNAMICS; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PEYRONIE DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUNICA ALBUGINEA; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 34447503353     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00470.x     Document Type: Review

References (69)

1. Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997; 157: 276-81.
2. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171: 2350-3.
3. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001; 88: 727-30.
4. Bella AJ, Sener A, Foell K, Brock GB. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: An atypical form of Peyronie's disease. J Sex Med 2006 October 11 [Epub ahead of print].
5. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Peyronie's disease. J Sex Med 2004; 1: 110-5.
6. Deveci S, Hopps CV, O'brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2006 November 1 [Epub ahead of print].
7. Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie's disease patients: Comparison of three methods. J Sex Med 2007; 4: 199-203.
8. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005; 11: 1073-85.
9. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
10. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, Harnden P, Thompson D, Eardley I, Banks RE, Knowles MA. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006; 119: 2642-50.
11. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007-9.
12. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970; 103: 75-6.
13. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-9.
14. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075-9.
15. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006; 175: 2115-8.
16. Fitch WP III, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - A placebo-controlled pilot study. J Sex Med 2007; 4: 477-84.
17. Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie's disease surgery: A comprehensive review. J Sex Med 2007; DOI: 10.1111/j.1743-6109.2007.00461.x.
18. Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. J Sex Med 2007; DOI: 10.1111/ j.1743-6109.2007.00453.x.
19. Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997; 157: 285-90.
20. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997; 158: 1388-90.
21. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997; 157: 311-5.
22. Lue TF. Peyronie's disease: An anatomically-based hypothesis and beyond. Int J Impot Res 2002; 14: 411-3.
23. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease. BJU Int 2003; 91: 830-8.
24. Jalkut M, Gonzalez-Cadavid N, Rajfer J. New discoveries in the basic science understanding of Peyronie's disease. Curr Urol Rep 2004; 5: 478-84.
25. el Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4.
26. Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 2005; 65: 645-8.
27. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002; 6: 283-94.
28. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002; 7: 262-76.
29. Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004; 71: 1568-77.
30. Mulhall JP. Expanding the paradigm for plaque development in Peyronie's disease. Int J Impot Res 2003; 15 (suppl 5): S93-102.
31. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB, Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1-9.
32. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
33. Border WA, Noble NA. Cytokines in kidney disease: The role of transforming growth factor-beta. Am J Kidney Dis 1993; 22: 105-13.
34. el Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997; 158: 2284-90.
35. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397-405.
36. Luangkhot R, Rutchik S, Agarwal V, Puglia K, Bhargava G, Melman A. Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J Urol 1992; 148: 467-71.
37. Chiang PH, Chiang CP, Shen MR, Huang CH, Wang CJ, Huang IY, Shieh TY. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie's disease. Eur Urol 1992; 21: 48-51.
38. Somers KD, Sismour EN, Wright GL Jr, Devine CJ Jr, Gilbert DA, Horton CE. Isolation and characterization of collagen in Peyronie's disease. J Urol 1989; 141: 629-31.
39. Stewart S, Malto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie's disease. J Urol 1994; 152: 105-6.
40. Magee TR, Qian A, Rajfer J, Sander FC, Levine LA, Gonzalez-Cadavid NF. Gene expression profiles in the Peyronie's disease plaque. Urology 2002; 59: 451-7.
41. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64: 399-404.
42. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998; 51: 511-5.
43. Guerneri S, Stioui S, Mantovani F, Austoni E, Simoni G. Multiple clonal chromosome abnormalities in Peyronie's disease. Cancer Genet Cytogenet 1991; 52: 181-5.
44. Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, Eickelberg O. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2006; 51: 255-61.
45. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71.
46. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie's disease. Int J Impot Res 2002; 14: 361-74.
47. Twyman RM. Principles of proteomics. Abingdon: BIOS Scientific Publishers 2004.
48. Patterson SD, Aebersold RH. Proteomics: The first decade and beyond. Nat Genet 2003; 33 (suppl): 311-23.
49. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64-71.
50. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60: 2299-301.
51. Patterson SD, Aebersold R. Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis 1995; 16: 1791-814.
52. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-92.
53. Hutchens T, Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993; 7: 576-80.
54. Aldred S, Grant MM, Griffiths HR. The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004; 37: 943-52.
55. Forde CE, McCutchen-Maloney SL. Characterization of transcription factors by mass spectrometry and the role of SELDI-MS. Mass Spectrom Rev 2002; 21: 419-39.
56. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: Their potential for disease diagnosis. Mol Cell Endocrinol 2005; 230: 95-106.
57. De Young L, Bella A, Howard J, Brock G. Arteriogenic erectile dysfunction alters protein expression within the cavernosal tissue in an animal model. J Sex Med 2005; 2: 199-206.
58. Kwapiszewska G, Meyer M, Bogumil R, Bohle RM, Seeger W, Weissmann N, Fink L. Identification of proteins in laser-microdissected small cell numbers by SELDI-TOF and tandem MS. BMC Biotechnol 2004; 4: 30.
59. Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002; 14: 406-10.
60. Hong H, Dragan Y, Epstein J, Teitel C, Chen B, Xie Q, Fang H, Shi L, Perkins R, Tong W. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 2005; 6 (suppl 2): S5.
61. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. Nature 2003; 422: 233-7.
62. MacNeil JS. Better biomarkers for the diagnostics labyrinth. Genome Technol 2004; 15: 24-33.
63. Sanchez JC, Corthals GL, Hochstrasser DF. Biomedical applications of proteomics. Weinheim: Wiley-VCH; 2004.
64. Albala JS, Humphery-Smith I. Protein arrays, biochips and proteomics: The next phase of genomic discovery. New York: Marcel Dekker; 2003.
65. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
66. Lin GT, Wang Z, Liu BC, Lue TF, Lin CS. Identification of potential biomarkers of Peyronie's disease. Asian J Androl 2005; 7: 237-43.
67. Lin CS, Lin G, Wang Z, Maddah SA, Lue TF. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002; 295: 1014-19.
68. De Young L, Bella A, Gan BS, Brock G. The pathogenesis of Peyronie's disease: A state of altered wound healing. J Sex Med 2006; 3 (suppl 1): 24.
69. Brock G, Bella A, Gan BS, De Young L. Use of SELDI to determine whether Peyrone's disease protein expression can predict progression. J Sex Med 2006; 3 (suppl 1): 18.